Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daptomycin

FDA-approved product (powder, intravenous), marketed as Cubicin, Cubicin Rf, Daptomycin and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Daptomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial endocarditis
  • Bacteriemia
  • Endocarditis
  • Gram-positive bacterial infections
  • Infection
  • Infective endocarditis
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibacterials
FDA pharmacologic class
Lipopeptide Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX09; FDA class Lipopeptide Antibacterial

Repurposing investigation

Daptomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Daptomycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daptomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Initial Treatment for Acute Bacterial Skin Infections (ABSSSI) Caused by Staphylococcus Aureus

    NCT01211470 · start 2010-10

    Registered record
    Registry ID
    NCT01211470
    Conditions
    Acute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA); (Susceptible or Methicillin Resistant)
    Interventions
    Daptomycin; PMX-30063-investigational drug
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10
    Completion
    2012-03
    Enrolment
    215

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Bacterial Skin and Skin-structure Infection(ABSSSI) Due to Staphylococcus Aureus (MSSA); (Susceptible or Methicillin Resistant)
    InterventionDaptomycin; PMX-30063-investigational drug
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use

    NCT01219114 · start 2010-10

    Registered record
    Registry ID
    NCT01219114
    Conditions
    Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Withdrawn
    Start
    2010-10
    Completion
    2013-11
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis
    InterventionNot recorded
    PhaseNot recorded
    Registry statusWithdrawn

  • Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

    NCT01133600 · start 2010-08

    Registered record
    Registry ID
    NCT01133600
    Conditions
    Diabetic Foot
    Interventions
    Cubicin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-08
    Completion
    2012-08
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Foot
    InterventionCubicin; Vancomycin
    PhasePhase 4
    Registry statusTerminated

  • Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting

    NCT01175707 · start 2010-07-15

    Registered record
    Registry ID
    NCT01175707
    Conditions
    Complicated Skin or Skin Structure Infection
    Interventions
    Daptomycin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-07-15
    Completion
    2011-11-17
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Skin or Skin Structure Infection
    InterventionDaptomycin; Vancomycin
    PhasePhase 4
    Registry statusTerminated

  • Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections

    NCT01184872 · start 2010-03

    Registered record
    Registry ID
    NCT01184872
    Conditions
    Infections
    Interventions
    Daptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-03
    Completion
    2011-03
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections
    InterventionDaptomycin; Vancomycin or Semi-Synthetic Penicillins (SSPs)
    PhasePhase 3
    Registry statusCompleted

  • Daptomycin Pharmacokinetics in Continuous Veno-venous Hemodiafiltration

    NCT01171547 · start 2010-02

    Registered record
    Registry ID
    NCT01171547
    Conditions
    Bacteremia
    Interventions
    Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2010-02
    Completion
    Not recorded
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionDaptomycin
    PhasePhase 2
    Registry statusUnknown

  • Daptomycin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-venous Hemodiafiltration, a Dose Finding Study

    NCT01212432 · start 2009-12

    Registered record
    Registry ID
    NCT01212432
    Conditions
    Gram-Positive Bacterial Infections
    Interventions
    Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2009-12
    Completion
    2010-03
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGram-Positive Bacterial Infections
    InterventionDaptomycin
    PhasePhase 2
    Registry statusUnknown

  • Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

    NCT01012089 · start 2009-11

    Registered record
    Registry ID
    NCT01012089
    Conditions
    Chronic Kidney Disease; Bacterial Infection
    Interventions
    Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-11
    Completion
    2014-04
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Kidney Disease; Bacterial Infection
    InterventionDaptomycin
    PhaseNot applicable
    Registry statusCompleted

  • Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)

    NCT00638157 · start 2009-02-13

    Registered record
    Registry ID
    NCT00638157
    Conditions
    Infective Endocarditis
    Interventions
    daptomycin; daptomycin and gentamicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2009-02-13
    Completion
    2011-11-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfective Endocarditis
    Interventiondaptomycin; daptomycin and gentamicin
    PhasePhase 4
    Registry statusTerminated

  • Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia

    NCT00695903 · start 2008-09-17

    Registered record
    Registry ID
    NCT00695903
    Conditions
    Endocarditis, Bacterial; Infective Endocarditis
    Interventions
    daptomycin; vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-09-17
    Completion
    2010-10-01
    Enrolment
    38

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndocarditis, Bacterial; Infective Endocarditis
    Interventiondaptomycin; vancomycin
    PhasePhase 2
    Registry statusTerminated

  • Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections

    NCT00711802 · start 2008-07-23

    Registered record
    Registry ID
    NCT00711802
    Conditions
    Skin Diseases, Infectious
    Interventions
    Daptomycin; Standard of Care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07-23
    Completion
    2013-10-11
    Enrolment
    396

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Diseases, Infectious
    InterventionDaptomycin; Standard of Care (SOC)
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery

    NCT00701636 · start 2008-07

    Registered record
    Registry ID
    NCT00701636
    Conditions
    Late Effects of Surgery; Staphylococcus Aureus; Surgical Site Infection
    Interventions
    daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-07
    Completion
    2010-10
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLate Effects of Surgery; Staphylococcus Aureus; Surgical Site Infection
    Interventiondaptomycin
    PhasePhase 3
    Registry statusCompleted

  • A Pilot Study of Daptomycin for Antimicrobial Prophylaxis

    NCT00572260 · start 2008-01

    Registered record
    Registry ID
    NCT00572260
    Conditions
    Antimicrobial Prophylaxis
    Interventions
    daptomycin 6 mg/kg IV
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2008-01
    Completion
    2008-09
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntimicrobial Prophylaxis
    Interventiondaptomycin 6 mg/kg IV
    PhasePhase 4
    Registry statusTerminated

  • Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis

    NCT00967941 · start 2007-08

    Registered record
    Registry ID
    NCT00967941
    Conditions
    MRSA Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2007-08
    Completion
    2010-08
    Enrolment
    169

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMRSA Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

    NCT00463801 · start 2007-01

    Registered record
    Registry ID
    NCT00463801
    Conditions
    Staphylococcal Skin Infections
    Interventions
    Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2007-01
    Completion
    Not recorded
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Skin Infections
    InterventionDaptomycin
    PhasePhase 4
    Registry statusTerminated